library.onepin.app/bpc-157-arginate Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Repair & Recovery

Repair & Recovery Gastric Pentadecapeptide Not FDA-approved · investigational

BPC-157 Arginate

BPC-157 Arginate Salt

Gastric PentadecapeptideTissue RepairCytoprotectiveStable Salt Form

BPC-157 Arginate (also called BPC-157 Arginine Salt) is a stable salt form of the gastric pentadecapeptide BPC-157, where the peptide is complexed with L-arginine. This formulation was developed to improve the stability and oral bioavailability of BPC-157, as the arginine salt form is more resistant to degradation in the gastrointestinal tract.

Quick Start
Route
Subcutaneous (SubQ) or Oral
Start low
250-500mcg
Frequency
1-2x daily
Timing
No fasting required (oral: empty stomach preferred)

Same timing as standard BPC-157. Can be taken any time. Empty stomach for oral dosing.

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
250-500mcg · Subcutaneous (SubQ) or Oral · 1-2x daily
Lowest starting point. Hold about a week to assess tolerance before stepping up.
250-500mcg
1-2x daily
Standard
Gastric Healing (Oral)
250-500 mcg · Oral · 2x Daily
animal study · Sikiric et al. 2011 (Curr Pharm Des, 17:1612-32; PMID 21548867)
250-500 mcg
2x Daily
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

Identical mechanism to standard BPC-157: upregulates VEGF and eNOS for angiogenesis, modulates the NO system, promotes FAK-paxillin pathway for cell migration, and increases GH receptor expression. The arginine salt form provides a counterion that stabilizes the peptide structure, particularly in low-pH environments like the stomach. Arginine itself is a nitric oxide precursor, which may provide a minor additive benefit to BPC-157's own NO-modulating effects.

Identical mechanism to standard BPC-157: upregulates VEGF and eNOS for angiogenesis, modulates the NO system, promotes FAK-paxillin pathway for cell migration, and increases GH receptor expression. The arginine salt form provides a counterion that stabilizes the peptide structure, particularly in low-pH environments like the stomach. Arginine itself is a nitric oxide precursor, which may provide a minor additive benefit to BPC-157's own NO-modulating effects.

02

What to expect

Early
Days 1–7

Days 1-7: Reduced inflammation and pain at injury site. Gut issues may show early improvement. Same rapid onset as standard BPC-157.

03

Evidence

HumanNo published trials
AnimalStrong
In-vitroPresent
2021Stable Gastric Pentadecapeptide BPC 157 and Wound Healing · Sikiric P et al, Frontiers in Pharmacology ↗review
2015Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro · Huang T et al, Drug Design, Development and Therapy ↗peer reviewed
2011The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration · Chang CH et al, Journal of Applied Physiology ↗peer reviewed
2019Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing · Gwyer D et al, Cell and Tissue Research ↗review
04

The honest take

Arginate form is significantly better than standard BPC-157

Partly true

Partially supported. The arginate salt form does show improved acid stability, which is meaningful for oral administration. For injectable use, the difference is likely negligible since both forms deliver the same active peptide into the bloodstream.

Only the arginate form works orally
Overstated

Overstated. Standard BPC-157 (acetate) is already acid-stable due to its amino acid sequence. The arginate form may provide incrementally better oral bioavailability, but standard BPC-157 has extensive oral efficacy data in animal studies.

05

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

GHK-CuBPC tissue repair + GHK-Cu collagen remodeling.
KPVBPC targets tissue repair, KPV targets inflammation. Gut healing combo.
TB-500Wolverine Stack: BPC drives angiogenesis/NO, TB drives actin/cell migration.

Keep separate

CJC-1295 with DACDAC maleimide group may react with BPC. Pin separately.
NAD+Acidic pH of NAD+ can denature BPC-157.
06

Side effects & safety

Commonly reported

  • Mild injection site redness (resolves quickly)
  • Occasional lightheadedness post-injection
  • Mild GI changes during gut healing phase

Less common & notes

  • Same exceptionally favorable safety profile as standard BPC-157.
  • No LD50 established in animal studies.
  • Long-term human safety data does not exist for either form.
07

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
~2 min (plasma), ~4-6h biological activity
Peak · Tmax
Rapid (minutes)
Elimination
~20h
Activity
4-6 hours (tissue repair signaling via VEGF/eNOS persists well beyond plasma half-life)

Storage. Reconstitute with bacteriostatic water for injection. Store refrigerated at 2-8C. Same stability as standard BPC-157 - 28-30 days after reconstitution. For oral use, some users dissolve in water and drink. Do not freeze after reconstitution.

08

Regulatory status

Not FDA-approved for any indication. Same regulatory status as standard BPC-157 - available through compounding pharmacies and research suppliers. All human use is experimental/off-label.

Put it to work

Calculate, log & track

Open BPC-157 Arginate straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open BPC-157 Arginate in the app →

Go deeper

The guide & community

The complete BPC-157 Arginate walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community